LENZ Therapeutics (LENZ) Income towards Parent Company (2020 - 2026)

LENZ Therapeutics (LENZ) has 7 years of Income towards Parent Company data on file, last reported at -$42.2 million in Q1 2026.

• On a quarterly basis, Income towards Parent Company fell 165.34% year-over-year to -$42.2 million in Q1 2026; TTM through Mar 2026 was -$109.7 million, a 123.78% decrease from a year earlier, with the FY2025 full-year figure at -$82.1 million, down 65.02% from the prior year.
• Income towards Parent Company for Q1 2026 stood at -$42.2 million, down from -$35.9 million in the prior quarter.
• Over the last five years, Income towards Parent Company for LENZ reached as high as -$10.2 million in Q3 2024 and fell as low as -$636.4 million in Q2 2022.
• Historically, Income towards Parent Company has averaged -$61.2 million across 5 years, with a median of -$18.2 million in 2023.
• Across the five-year window, Income towards Parent Company slumped 387.6% in 2022 and surged 92.18% in 2023, its largest moves.
• Year by year, Income towards Parent Company stood at -$28.3 million in 2022, then jumped by 35.87% to -$18.2 million in 2023, then surged by 30.4% to -$12.7 million in 2024, then slumped by 183.72% to -$35.9 million in 2025, then decreased by 17.58% to -$42.2 million in 2026.
• Per Business Quant data, the three most recent Income towards Parent Company figures were -$42.2 million in Q1 2026, -$35.9 million in Q4 2025, and -$16.7 million in Q3 2025.